PMID- 30167776 OWN - NLM STAT- MEDLINE DCOM- 20190529 LR - 20210323 IS - 1437-1596 (Electronic) IS - 0937-9827 (Linking) VI - 133 IP - 3 DP - 2019 May TI - Post-mortem in situ stability of serum markers of cerebral damage and acute phase response. PG - 871-881 LID - 10.1007/s00414-018-1925-2 [doi] AB - The aim of the given study was to test the in situ stability of biochemical markers of cerebral damage and acute phase response in the early post-mortem interval to assess their usability for forensic pathology. A monocentric, prospective study investigated post-mortem femoral venous blood samples at four time points obtained within 48 h post-mortem starting at the death of 20 deceased, using commercial immunoassays for the ten parameters: S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT), ferritin, soluble tumor necrosis factor receptor type 1 (sTNFR1), and lactate dehydrogenase (LDH). Significant changes in serum levels were observed only later than 2 h after death for all markers. Inter-laboratory comparability was high, and intra-assay precision was sufficient for most markers. Most of the biomarker levels depended on the severity of hemolysis and lipemia but were robust against freeze-thaw cycles. Serum levels increased with longer post-mortem intervals for S100B, NSE, ferritin, sTNFR1, and LDH (for all p < 0.001) but decreased over this period for CRP (p = 0.089) and PCT (p < 0.001). Largely unchanged median values were found for GFAP (p = 0.139), BDNF (p = 0.106), and IL-6 (p = 0.094). Serum levels of CRP (p = 0.059) and LDH (p = 0.109) did not differ significantly between the final ante-mortem (resuscitation) and the first post-mortem sample (moment of death). Collecting the post-mortem blood sample as soon as possible will reduce the influence of post-mortem blood changes. Serum GFAP for detection of cerebral damage as well as serum IL-6 and CRP as proof of acute phase response seemed to be preferable due to their in situ stability in the first 2 days after death. FAU - Ondruschka, Benjamin AU - Ondruschka B AD - Medical Faculty, Institute of Legal Medicine, University of Leipzig, Johannisallee 28, 04103, Leipzig, Germany. benjamin.ondruschka@medizin.uni-leipzig.de. FAU - Woydt, Lina AU - Woydt L AD - Medical Faculty, Institute of Legal Medicine, University of Leipzig, Johannisallee 28, 04103, Leipzig, Germany. FAU - Bernhard, Michael AU - Bernhard M AD - Emergency Department, Heinrich Heine University Duesseldorf, Duesseldorf, Germany. FAU - Franke, Heike AU - Franke H AD - Rudolf Boehm Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany. FAU - Kirsten, Holger AU - Kirsten H AD - Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. AD - LIFE Center (Leipzig Interdisciplinary Research Cluster of Genetic Factors, Phenotypes and Environment), University of Leipzig, Leipzig, Germany. FAU - Loffler, Sabine AU - Loffler S AD - Institute of Anatomy, University of Leipzig, Leipzig, Germany. FAU - Pohlers, Dirk AU - Pohlers D AD - Center of Diagnostics GmbH, Klinikum Chemnitz, Chemnitz, Germany. FAU - Hammer, Niels AU - Hammer N AD - Department of Anatomy, University of Otago, Dunedin, New Zealand. AD - Department of Orthopedic and Trauma Surgery, University Hospital of Leipzig, Leipzig, Germany. AD - Fraunhofer Institute for Machine Tools and Forming Technology, Dresden, Germany. FAU - Dressler, Jan AU - Dressler J AD - Medical Faculty, Institute of Legal Medicine, University of Leipzig, Johannisallee 28, 04103, Leipzig, Germany. LA - eng PT - Journal Article DEP - 20180830 PL - Germany TA - Int J Legal Med JT - International journal of legal medicine JID - 9101456 RN - 0 (Biomarkers) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Glial Fibrillary Acidic Protein) RN - 0 (Interleukin-6) RN - 0 (Procalcitonin) RN - 0 (Receptors, Tumor Necrosis Factor, Type I) RN - 0 (S100 Calcium Binding Protein beta Subunit) RN - 0 (S100B protein, human) RN - 9007-41-4 (C-Reactive Protein) RN - 9007-73-2 (Ferritins) RN - EC 1.1.1.27 (L-Lactate Dehydrogenase) RN - EC 4.2.1.11 (Phosphopyruvate Hydratase) SB - IM MH - *Acute-Phase Reaction MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers/*blood MH - Brain Injuries/*blood MH - Brain-Derived Neurotrophic Factor/blood MH - C-Reactive Protein/analysis MH - Female MH - Ferritins/blood MH - Glial Fibrillary Acidic Protein/blood MH - Humans MH - Immunoassay MH - Interleukin-6/blood MH - L-Lactate Dehydrogenase/blood MH - Male MH - Middle Aged MH - Phosphopyruvate Hydratase/blood MH - *Postmortem Changes MH - Procalcitonin/blood MH - Prospective Studies MH - Receptors, Tumor Necrosis Factor, Type I/blood MH - S100 Calcium Binding Protein beta Subunit/blood OTO - NOTNLM OT - Acute phase response OT - Intra-individual stability OT - Post-mortem biochemistry OT - Serum OT - Thanatochemistry OT - Traumatic brain injury EDAT- 2018/09/01 06:00 MHDA- 2019/05/30 06:00 CRDT- 2018/09/01 06:00 PHST- 2018/07/05 00:00 [received] PHST- 2018/08/23 00:00 [accepted] PHST- 2018/09/01 06:00 [pubmed] PHST- 2019/05/30 06:00 [medline] PHST- 2018/09/01 06:00 [entrez] AID - 10.1007/s00414-018-1925-2 [pii] AID - 10.1007/s00414-018-1925-2 [doi] PST - ppublish SO - Int J Legal Med. 2019 May;133(3):871-881. doi: 10.1007/s00414-018-1925-2. Epub 2018 Aug 30.